BDNF and Alzheimer disease: AD rats treated with A. esculentus seed extract displayed remarkable improvements in BDNF, glycated end product, and IL-6 amounting to 26.5, 163.7, and 213.5%, in comparison with the reference drug, which showed improvements of 35.2, 219.6, and 229.4% for BDNF, AGEs and IL-6, respectively (Table 3).